Nature Medicine, volume 28, issue 11, pages 2374-2380
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
Gogishvili Miranda
1
,
Melkadze Tamar
2
,
Makharadze Tamta
3
,
Giorgadze Davit
4
,
Dvorkin Mikhail
5
,
Penkov Konstantin
6
,
Laktionov Konstantin
7
,
Nemsadze Gia
8
,
Nechaeva Marina
9
,
Rozhkova Irina
10
,
Kalinka Ewa
11
,
Gessner Christian
12, 13
,
Moreno Jaime Brizio
14
,
Passalacqua Rodolfo
15
,
Li Siyu
16
,
McGuire Kristina
16
,
Kaul Manika
16
,
Paccaly Anne
16
,
Quek Ruben G. W.
16
,
Gao Bo
16
,
Seebach Frank
16
,
Weinreich David M.
16
,
Yancopoulos George D.
16
,
Lowy Israel
16
,
Gullo Giuseppe
16
,
Rietschel Petra
16
1
High Technology Medical Centre, University Clinic Ltd., Tbilisi, Georgia
|
2
Acad. F. Todua Medical Center, Tbilisi, Georgia
|
3
LTD High Technology Hospital Med Center, Batumi, Georgia
|
5
State Budgetary Healthcare Institution of Omsk Region, Omsk, Russia
|
6
Private Medical Institution Euromedservice, Saint Petersburg, Russia
|
8
The Institute of Clinical Oncology, Tbilisi, Georgia
|
9
Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Chelyabinsk, Russia
|
10
Kaluga Regional Clinical Oncology Dispensary, Kaluga, Russia
|
11
Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland
|
12
Institute of Clinical Immunology, University of Leipzig, Leipzig, Germany
|
13
POIS Leipzig GbR, Leipzig, Germany
|
14
Hospital Regional ISSSTE, León, Mexico
|
15
Istituti Ospitalieri Di Cremona, Cremona, Italy
|
16
Regeneron Pharmaceuticals, Inc., Tarrytown, USA
|
Publication type: Journal Article
Publication date: 2022-08-25
Journal:
Nature Medicine
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor: 82.9
ISSN: 10788956, 1546170X
General Biochemistry, Genetics and Molecular Biology
General Medicine
Abstract
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) and PD-ligand 1 (PD-L1) expression ≥50%. EMPOWER-Lung 3 ( NCT03409614 ), a double-blind, placebo-controlled, phase 3 study, examined cemiplimab plus platinum-doublet chemotherapy as first-line treatment for aNSCLC, irrespective of PD-L1 expression or histology. In this study, 466 patients with stage III/IV aNSCLC without EGFR, ALK or ROS1 genomic tumor aberrations were randomized (2:1) to receive cemiplimab 350 mg (n = 312) or placebo (n = 154) every 3 weeks for up to 108 weeks in combination with four cycles of platinum-doublet chemotherapy (followed by pemetrexed maintenance as indicated). In total, 57.1% (266/466 patients) had non-squamous NSCLC, and 85.2% (397/466 patients) had stage IV disease. The primary endpoint was OS. The trial was stopped early per recommendation of the independent data monitoring committee, based on meeting preset OS efficacy criteria: median OS was 21.9 months (95% confidence interval (CI), 15.5–not evaluable) with cemiplimab plus chemotherapy versus 13.0 months (95% CI, 11.9–16.1) with placebo plus chemotherapy (hazard ratio (HR) = 0.71; 95% CI, 0.53–0.93; P = 0.014). Grade ≥3 adverse events occurred with cemiplimab plus chemotherapy (43.6%, 136/312 patients) and placebo plus chemotherapy (31.4%, 48/153 patients). Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in aNSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies. Results from EMPOWER-Lung 3 demonstrate increased overall survival with cemiplimab plus platinum-doublet chemotherapy compared to cemiplimab as first-line treatment in patients with advanced non-small cell lung cancer, irrespective of PD-L1 expression.
Citations by journals
|
1
2
3
4
5
6
7
|
|
|
Cancers
|
Cancers
7 publications, 9.33%
|
|
Frontiers in Oncology
|
Frontiers in Oncology
6 publications, 8%
|
|
Journal of Thoracic Oncology
|
Journal of Thoracic Oncology
4 publications, 5.33%
|
|
Frontiers in Immunology
|
Frontiers in Immunology
3 publications, 4%
|
|
Journal of Clinical Medicine
|
Journal of Clinical Medicine
2 publications, 2.67%
|
|
Biomedicines
|
Biomedicines
2 publications, 2.67%
|
|
Lung Cancer
|
Lung Cancer
2 publications, 2.67%
|
|
Journal of Clinical Oncology
|
Journal of Clinical Oncology
2 publications, 2.67%
|
|
Clinical Lung Cancer
|
Clinical Lung Cancer
2 publications, 2.67%
|
|
Cancer Treatment and Research Communications
|
Cancer Treatment and Research Communications
2 publications, 2.67%
|
|
BMC Cancer
|
BMC Cancer
2 publications, 2.67%
|
|
ESMO Open
|
ESMO Open
1 publication, 1.33%
|
|
Cancer Treatment Reviews
|
Cancer Treatment Reviews
1 publication, 1.33%
|
|
Nature Reviews Clinical Oncology
|
Nature Reviews Clinical Oncology
1 publication, 1.33%
|
|
Annals of Oncology
|
Annals of Oncology
1 publication, 1.33%
|
|
Journal of Hematology and Oncology
|
Journal of Hematology and Oncology
1 publication, 1.33%
|
|
PLoS ONE
|
PLoS ONE
1 publication, 1.33%
|
|
Hematology/Oncology Clinics of North America
|
Hematology/Oncology Clinics of North America
1 publication, 1.33%
|
|
Journal of the National Cancer Institute
|
Journal of the National Cancer Institute
1 publication, 1.33%
|
|
Pneumo News
|
Pneumo News
1 publication, 1.33%
|
|
Lung Cancer: Targets and Therapy
|
Lung Cancer: Targets and Therapy
1 publication, 1.33%
|
|
Current Oncology
|
Current Oncology
1 publication, 1.33%
|
|
Cancer Management and Research
|
Cancer Management and Research
1 publication, 1.33%
|
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
1 publication, 1.33%
|
|
Pharmaceutics
|
Pharmaceutics
1 publication, 1.33%
|
|
Bulletin du Cancer
|
Bulletin du Cancer
1 publication, 1.33%
|
|
Frontiers in Pharmacology
|
Frontiers in Pharmacology
1 publication, 1.33%
|
|
Journal for ImmunoTherapy of Cancer
|
Journal for ImmunoTherapy of Cancer
1 publication, 1.33%
|
|
Clinical Oncology
|
Clinical Oncology
1 publication, 1.33%
|
|
1
2
3
4
5
6
7
|
Citations by publishers
|
5
10
15
20
25
|
|
|
Elsevier
|
Elsevier
21 publications, 28%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
15 publications, 20%
|
|
Frontiers Media S.A.
|
Frontiers Media S.A.
10 publications, 13.33%
|
|
Springer Nature
|
Springer Nature
9 publications, 12%
|
|
Wiley
|
Wiley
3 publications, 4%
|
|
BMJ
|
BMJ
2 publications, 2.67%
|
|
American Society of Clinical Oncology (ASCO)
|
American Society of Clinical Oncology (ASCO)
2 publications, 2.67%
|
|
Dove Medical Press
|
Dove Medical Press
2 publications, 2.67%
|
|
Public Library of Science (PLoS)
|
Public Library of Science (PLoS)
1 publication, 1.33%
|
|
Oxford University Press
|
Oxford University Press
1 publication, 1.33%
|
|
Wolters Kluwer Health
|
Wolters Kluwer Health
1 publication, 1.33%
|
|
AME Publishing Company
|
AME Publishing Company
1 publication, 1.33%
|
|
Neoplasia Press
|
Neoplasia Press, 1, 1.33%
Neoplasia Press
1 publication, 1.33%
|
|
Taylor & Francis
|
Taylor & Francis
1 publication, 1.33%
|
|
Future Medicine
|
Future Medicine
1 publication, 1.33%
|
|
5
10
15
20
25
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2022,2023,2024],"ids":[0,0,0],"codes":[0,0,0],"imageUrls":["","",""],"datasets":[{"label":"Citations number","data":[4,54,17],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6"],"percentage":["5.33","72","22.67"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Cancers","Frontiers in Oncology","Journal of Thoracic Oncology","Frontiers in Immunology","Journal of Clinical Medicine","Biomedicines","Lung Cancer","Journal of Clinical Oncology","Clinical Lung Cancer","Cancer Treatment and Research Communications","BMC Cancer","ESMO Open","Cancer Treatment Reviews","Nature Reviews Clinical Oncology","Annals of Oncology","Journal of Hematology and Oncology","PLoS ONE","Hematology\/Oncology Clinics of North America","Journal of the National Cancer Institute","Pneumo News","Lung Cancer: Targets and Therapy","Current Oncology","Cancer Management and Research","International Journal of Molecular Sciences","Pharmaceutics","Bulletin du Cancer","Frontiers in Pharmacology","Journal for ImmunoTherapy of Cancer","Clinical Oncology"],"ids":[22471,10990,22450,1699,26234,24421,15451,20231,16044,3393,6868,4008,3808,6763,3443,20917,24963,19352,22765,35731,16099,11066,17233,14627,4502,9992,9788,7901,4582],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/0WrbuCPHoMon4eqSaqLoeO1owjv6jeDiHASSYzbS_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/hysFKdIDQMKHPbF1uLxJ3M6dQA4gPVuC6ZeA7m5a_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/hysFKdIDQMKHPbF1uLxJ3M6dQA4gPVuC6ZeA7m5a_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp"],"datasets":[{"label":"","data":[7,6,4,3,2,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[9.33,8,5.33,4,2.67,2.67,2.67,2.67,2.67,2.67,2.67,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33,1.33],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Elsevier","Multidisciplinary Digital Publishing Institute (MDPI)","Frontiers Media S.A.","Springer Nature","Wiley","BMJ","American Society of Clinical Oncology (ASCO)","Dove Medical Press","Public Library of Science (PLoS)","Oxford University Press","Wolters Kluwer Health","AME Publishing Company","Neoplasia Press","Taylor & Francis","Future Medicine"],"ids":[17,202,208,8,11,6954,73,417,344,19,32,1566,4513,18,6949],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/hysFKdIDQMKHPbF1uLxJ3M6dQA4gPVuC6ZeA7m5a_medium.webp","\/storage\/images\/resized\/0WrbuCPHoMon4eqSaqLoeO1owjv6jeDiHASSYzbS_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/PRGhlgB4OKRltSNtT39eA6wlnOTGRap1QQ6FQHih_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/PYBAYQjpFdxPQPRGY3kU5Xzbu0W7K7umVNk0TY9i_medium.webp","","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp"],"datasets":[{"label":"","data":[21,15,10,9,3,2,2,2,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[28,20,13.33,12,4,2.67,2.67,2.67,1.33,1.33,1.33,1.33,1.33,1.33,1.33],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Gogishvili M. et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial // Nature Medicine. 2022. Vol. 28. No. 11. pp. 2374-2380.
GOST all authors (up to 50)
Copy
Gogishvili M., Melkadze T., Makharadze T., Giorgadze D., Dvorkin M., Penkov K., Laktionov K., Nemsadze G., Nechaeva M., Rozhkova I., Kalinka E., Gessner C., Moreno Jaime B., Passalacqua R., Li S., McGuire K., Kaul M., Paccaly A., Quek R. G. W., Gao B., Seebach F., Weinreich D. M., Yancopoulos G. D., Lowy I., Gullo G., Rietschel P. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial // Nature Medicine. 2022. Vol. 28. No. 11. pp. 2374-2380.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/s41591-022-01977-y
UR - https://doi.org/10.1038%2Fs41591-022-01977-y
TI - Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
T2 - Nature Medicine
AU - Gogishvili, Miranda
AU - Melkadze, Tamar
AU - Makharadze, Tamta
AU - Giorgadze, Davit
AU - Dvorkin, Mikhail
AU - Penkov, Konstantin
AU - Laktionov, Konstantin
AU - Nemsadze, Gia
AU - Nechaeva, Marina
AU - Rozhkova, Irina
AU - Kalinka, Ewa
AU - Gessner, Christian
AU - Moreno Jaime, Brizio
AU - Passalacqua, Rodolfo
AU - Li, Siyu
AU - McGuire, Kristina
AU - Kaul, Manika
AU - Paccaly, Anne
AU - Quek, Ruben G. W.
AU - Gao, Bo
AU - Seebach, Frank
AU - Weinreich, David M.
AU - Yancopoulos, George D.
AU - Lowy, Israel
AU - Gullo, Giuseppe
AU - Rietschel, Petra
PY - 2022
DA - 2022/08/25 00:00:00
PB - Springer Nature
SP - 2374-2380
IS - 11
VL - 28
SN - 1078-8956
SN - 1546-170X
ER -
Cite this
BibTex
Copy
@article{2022_Gogishvili,
author = {Miranda Gogishvili and Tamar Melkadze and Tamta Makharadze and Davit Giorgadze and Mikhail Dvorkin and Konstantin Penkov and Konstantin Laktionov and Gia Nemsadze and Marina Nechaeva and Irina Rozhkova and Ewa Kalinka and Christian Gessner and Brizio Moreno Jaime and Rodolfo Passalacqua and Siyu Li and Kristina McGuire and Manika Kaul and Anne Paccaly and Ruben G. W. Quek and Bo Gao and Frank Seebach and David M. Weinreich and George D. Yancopoulos and Israel Lowy and Giuseppe Gullo and Petra Rietschel},
title = {Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial},
journal = {Nature Medicine},
year = {2022},
volume = {28},
publisher = {Springer Nature},
month = {aug},
url = {https://doi.org/10.1038%2Fs41591-022-01977-y},
number = {11},
pages = {2374--2380},
doi = {10.1038/s41591-022-01977-y}
}
Cite this
MLA
Copy
Gogishvili, Miranda, et al. “Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.” Nature Medicine, vol. 28, no. 11, Aug. 2022, pp. 2374-2380. https://doi.org/10.1038%2Fs41591-022-01977-y.